Przejdź do zawartości
Merck

Type I, II, and III interferon signatures correspond to COVID-19 disease severity.

medRxiv : the preprint server for health sciences (2021-03-25)
Myung-Ho Kim, Shadi Salloum, Jeffrey Y Wang, Lai Ping Wong, James Regan, Kristina Lefteri, Zachary Manickas-Hill, Jonathan Z Li, Ruslan I Sadreyev, Xu G Yu, Raymond T Chung
ABSTRAKT

We analyzed the plasma levels of interferons and cytokines, and the expression of interferon-stimulated genes in peripheral blood mononuclear cells in COVID-19 patients with different disease severity. Mild patients exhibited transient type I interferon responses, while ICU patients had prolonged type I interferon responses with hyper-inflammation mediated by interferon regulatory factor 1. Type II interferon responses were compromised in ICU patients. Type III interferon responses were induced in the early phase of SARS-CoV-2 infection, even in convalescent patients. These results highlight the importance of type I and III interferon responses during the early phase of infection in controlling COVID-19 progression.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Millipore
MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Panel A - Immunology Multiplex Assay
Millipore
MILLIPLEX® Human Cytokine/Chemokine Magnetic Bead Panel II - Immunology Multiplex Assay, Simultaneously analyze multiple cytokine and chemokine biomarkers with Bead-Based Multiplex Assays using the Luminex technology, in human serum, plasma and cell culture samples.